Mackenzie Financial Corp Rigel Pharmaceuticals Inc Transaction History

Mackenzie Financial Corp

$66.8 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.12 - $1.57 $14,325 - $20,081	12,791 Added 36.67%	47,671 $70,000
Q4 2023 Jan 30, 2024	BUY	$0.72 - $1.56 $1,267 - $2,747	1,761 Added 5.32%	34,880 $50,000
Q3 2023 Oct 25, 2023	BUY	$1.07 - $1.39 $4,304 - $5,591	4,023 Added 13.83%	33,119 $35,000
Q1 2023 Apr 24, 2023	SELL	$1.25 - $2.0 $5,941 - $9,506	-4,753 Reduced 14.04%	29,096 $38,000
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $2,352 - $41,780	3,511 Added 11.57%	33,849 $50,000
Q3 2022 Oct 07, 2022	SELL	$1.1 - $12.2 $5,054 - $56,059	-4,595 Reduced 13.15%	30,338 $36,000
Q2 2022 Aug 10, 2022	BUY	$0.67 - $3.19 $10,025 - $47,735	14,964 Added 74.94%	34,933 $39,000
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $1,725 - $2,609	-731 Reduced 3.53%	19,969 $53,000
Q3 2021 Nov 08, 2021	BUY	$3.5 - $4.5 $14,591 - $18,760	4,169 Added 25.22%	20,700 $75,000
Q2 2021 Aug 11, 2021	BUY	$3.09 - $4.54 $18,017 - $26,472	5,831 Added 54.5%	16,531 $72,000
Q1 2021 May 14, 2021	SELL	$3.35 - $4.93 $4,690 - $6,902	-1,400 Reduced 11.57%	10,700 $37,000
Q3 2020 Nov 13, 2020	SELL	$1.78 - $4.13 $3,560 - $8,260	-2,000 Reduced 14.18%	12,100 $29,000
Q2 2020 Aug 13, 2020	BUY	$1.41 - $2.05 $19,881 - $28,904	14,100 New	14,100 $25,000
Q2 2018 Aug 13, 2018	SELL	$2.83 - $4.11 $218,422 - $317,213	-77,181 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$3.54 - $4.54 $46,441 - $59,560	13,119 Added 20.48%	77,181 $273,000
Q4 2017 Feb 13, 2018	BUY	$3.23 - $4.3 $61,663 - $82,091	19,091 Added 42.45%	64,062 $249,000
Q3 2017 Nov 13, 2017	BUY	$2.18 - $2.57 $14,089 - $16,609	6,463 Added 16.78%	44,971 $114,000
Q2 2017 Aug 14, 2017	BUY	N/A	38,508	38,508 $105,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.

Account